169 related articles for article (PubMed ID: 35098345)
1. Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.
Lim CM; Liou A; Poon M; Koh LP; Tan LK; Loh KS; Petersson BF; Ting E; Campana D; Goh BC; Shimasaki N
Cancer Immunol Immunother; 2022 Sep; 71(9):2277-2286. PubMed ID: 35098345
[TBL] [Abstract][Full Text] [Related]
2. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
3. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
Ishikawa T; Okayama T; Sakamoto N; Ideno M; Oka K; Enoki T; Mineno J; Yoshida N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Kokura S; Uno K; Naito Y; Itoh Y
Int J Cancer; 2018 Jun; 142(12):2599-2609. PubMed ID: 29388200
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
Lee SC; Shimasaki N; Lim JSJ; Wong A; Yadav K; Yong WP; Tan LK; Koh LP; Poon MLM; Tan SH; Ow SGW; Bharwani L; Yap YS; Foo MZQ; Coustan-Smith E; Sundar R; Tan HL; Chong WQ; Kumarakulasinghe NB; Lieow JLM; Koe PJX; Goh BC; Campana D
Clin Cancer Res; 2020 Sep; 26(17):4494-4502. PubMed ID: 32522887
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study.
Choi MG; Son GW; Choi MY; Jung JS; Rho JK; Ji W; Yoon BG; Jo JM; Kim YM; Ko DH; Lee JC; Choi CM
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38538093
[TBL] [Abstract][Full Text] [Related]
9. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer.
Fasano M; Della Corte CM; Di Liello R; Barra G; Sparano F; Viscardi G; Iacovino ML; Paragliola F; Famiglietti V; Ciaramella V; Cimmino F; Capasso M; Iolascon A; Sforza V; Morabito A; Maiello E; Ciardiello F; Morgillo F
ESMO Open; 2020 Sep; 5(5):e000753. PubMed ID: 32912860
[TBL] [Abstract][Full Text] [Related]
10. Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway.
Long S; Gu Y; An Y; Lin X; Chen X; Wang X; Liao C; Ouyang W; Wang N; He Z; Zhao X
J Transl Med; 2021 May; 19(1):185. PubMed ID: 33933132
[TBL] [Abstract][Full Text] [Related]
11. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Chan AT; Hsu MM; Goh BC; Hui EP; Liu TW; Millward MJ; Hong RL; Whang-Peng J; Ma BB; To KF; Mueser M; Amellal N; Lin X; Chang AY
J Clin Oncol; 2005 May; 23(15):3568-76. PubMed ID: 15809453
[TBL] [Abstract][Full Text] [Related]
13. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
14. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
[TBL] [Abstract][Full Text] [Related]
15. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
17. Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.
Sun XS; Liang YJ; Li XY; Liu SL; Chen QY; Tang LQ; Mai HQ
Drug Des Devel Ther; 2019; 13():3207-3216. PubMed ID: 31686783
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
Yang Y; Zhou T; Chen X; Li J; Pan J; He X; Lin L; Shi YR; Feng W; Xiong J; Yang K; Yu Q; Zhang Q; Hu D; Sun Y; Hu G; Li P; Shen L; Lin Q; Zhang B; Qu X; Zou J; Zhang L; Fang W; Zhao Y
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933967
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
